

C?RE Diagnostics and Digistain revolutionise breast cancer care with new risk profiling technology

28 May 2024 | News

To predict the likelihood of post-surgery breast cancer recurrence



Gurugram-based C?RE Diagnostics, a leading clinical laboratory focused on next-generation diagnostics for disease stratification and therapy selection, has announced its exclusive partnership with Digistain. This collaboration aims to bring the UK's first Breast Cancer Risk Profiling Technology, Digistain, to India, Nepal, Bhutan and Bangladesh.

Digistain is a revolutionary digital solution for cancer grading and prognosis, approved by the UK's Medicines & Healthcare products Regulatory Agency (MHRA).

It offers a rapid, affordable, and artificial intelligence (AI)-enabled solution to predict the likelihood of post-surgery breast cancer recurrence. This technology is designed to prevent breast cancer patients from undergoing unnecessary chemotherapy.

Digistain has been developed with input from over 1,500 oncologists and has been successfully trialed at prominent cancer centres such as Nottingham University NHS Trust, the National Institute of Healthcare Research (NIHR) and Cancer Research UK.

The introduction of Digistain in India and its neighbouring states through this partnership is expected to revolutionise the healthcare industry's approach to breast cancer treatment. With its AI-enabled technology, Digistain has the potential to enhance diagnostic accuracy, reduce treatment costs, and ultimately save lives. This collaboration aligns with India's broader healthcare objectives of leveraging innovative solutions to address pressing healthcare challenges and improve patient care nationwide.